Search results for: Chronic Diseases
Filter search results
Immunisation for Everyone – The Polio Experience
1 September 1979
…effective and safe immunising techniques. There are today around 80 vaccines which protect against a wide range of infectious diseases. The purpose of this OHE briefing is to highlight key…
OHE Annual Lecture: Universal Health Coverage: the Holy Grail?
8 June 2014, 11:00pm
…1975 and pursued through WHO’s slogan Health for All. Recent policies have focussed on controlling specific diseases such as HIV and malaria and delivering specific interventions such as immunisation. In the…
OHE Lunchtime Seminar: Incentives for R&D, Competition and Intertemporal Effects of Payment Rules for Cures
5 June 2019, 11:00pm
…and pricing rules of pharmaceutical products do not account for intertemporal effects of cures for infectious diseases producing a positive intertemporal externality for future generations. This intuitively suggests that some…
Personalised Medicine: Is it an Oil-Rush or Oil-Spill?
3 February 2020, 12:00am
…is accompanied by an awareness of increased complexity in biologic knowledge. This increased biologic information has highlighted the general difficulty associated with personalized medicine. Generally, complex diseases are associated multiple…
The Role of Unmet Need in Pharmaceutical Innovation
19 October 2021, 11:00pm
…qualitative circumstances of each condition Balancing the needs in rare diseases alongside needs in more prevalent conditions Balancing patient and clinical perceptions of unmet needs against regulatory and payer perceptions…
News Release: Fighting Superbugs
6 July 2011
…eight different classes. The danger of resistant bacteria is that without effective treatment, diseases with traditionally high cure rates, such as pneumonia, become more difficult to treat. And “routine” procedures,…
Previews of Forthcoming Publications
27 July 2011
…of the problem of insufficient affordable medicines in developing countries and detail policies and proposals intended to increase access to global medicines. With respect to neglected diseases, the paper examines policies…
Collected Essays by Tony Culyer on Health Economics
25 November 2012
…achieving those objectives. Health technology assessment. This section presents essays illustrating Culyer’s three main intellectual contributions to health technology assessment: developing indicators of health that cross diseases, thinking that ultimately…
OHE Study on Pharmaceutical R&D Costs Released
3 December 2012
…600% from the 1970s[3] to the 2000s[4]. Second, success rates for clinical development are falling as tougher therapeutic areas are tackled—e.g. neurology (Alzheimer’s), autoimmune diseases (arthritis), and oncology. Success rates…